Summary
To establish whether additional therapy with 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase inhibitors enhances the low-density lipoprotein (LDL) cholesterol lowering effect of LDL apheresis with immunoadsorption in the treatment of patients with familial heterozygous hypercholesterolemia and coronary artery disease we studied eight patients initially on immunoadsorption therapy alone for 3 years. The adding of HMG CoA reductase inhibitors decreased pretreatment LDL cholesterol from 6.76±0.98 to 4.97±0.98 mmol/l and posttreatment LDL cholesterol from 2.33±0.80 to 1.94±0.67 mmol/l and increased pre- and posttreatment high-density lipoprotein (HDL) cholesterol by 0.08 and 0.13 mmol/l respectively. The LDL/HDL ratio was reduced from 4.0 to 2.8 (prior to any therapy the ratio was 13.4). The increase in LDL cholesterol between weekly treatments was less steep under the combined therapy. At the same time the treated plasma volume during LDL apheresis could be decreased from 5070±960 to 4370±1200 1200 ml. We conclude that in patients with severe familial heterozygous hypercholesterolemia LDL apheresis should be combined with HMG CoA reductase inhibitors.
Similar content being viewed by others
Abbreviations
- CoA:
-
coenzyme A
- HDL:
-
high-density lipoprotein
- HMG:
-
3-hydroxy-3-methylglutaryl
- LDL:
-
low-density lipoprotein
References
Borberg H, Gaczkowski A, Hombach V, Oette K, Stoffel W (1988) Regression of atherosclerosis in patients with familial hypercholesterolaemia under LDL-apheresis. Prog Clin Biol Res 255:317
Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289
Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W (1986) Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-Apherese. Dtsch Med Wochenschr 111:1709
Illingworth DR, Sexton GJ (1984) Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 74:1972
International Task Force for Prevention of Coronary Heart Disease (1992) Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 2:113
Iso H, Jacobs DRJ, Wentworth D, Neaton JD, Cohen JD (1989) Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904
Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007
Malloy MJ, Kane JP, Kunitake ST, Tun P (1987) Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 107:616
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1988) Report. Arch Intern Med 148:36
Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisl K. Schwandt P (1993) 3-Year treatment of familial heterozygous hypercholesterolemia by extracorporeal LDL immunoadsorption with polyclonal apoliprotein B antibodies. Metabolism (in press)
Stoffel W, Greve V, Borberg H (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet II:1005
Todd PA, Goa KL (1990) Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40:583
Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339:563
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. G. Paumgartner on the occasion of his 60th birthday
Rights and permissions
About this article
Cite this article
Jacob, B.G., Richter, W.O. & Schwandt, P. Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy. Clin Investig 71, 908–912 (1993). https://doi.org/10.1007/BF00185602
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00185602